Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

GWW to provide recycled water for a Victorian data centre

Valves, data centres and the invisible infrastructure of Australian industry

NVIDIA technology aims to give factories an AI brain

New Energy Transport secures funding to accelerate electric road freight

DroneShield marks global manufacturing milestone in Europe

Poultry and egg producers in lockdown as avian flu detected in WA

RMIT Food Innovation Hub to help advance food processing technology

Vacuum Cooling. The fix to your cooling bottleneck.

SAVE FOOD Initiative award winners from interpack

WA dog food manufacturer seals SE Asia export deal

Siemens expands Fusesaver manufacturing facility

BESS project provides long-duration battery for NSW

Lessons in long-distance telemetry

GECA and ACOR launch national standard for recycling

Antibiotics in wastewater may contribute to antimicrobial resistance